Gilead Sciences, Inc. (NASDAQ:GILD)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $69.40, but opened at $72.23. Gilead Sciences shares last traded at $73.97, with a volume of 9588172 shares traded.
GILD has been the topic of a number of recent analyst reports. Mizuho reissued a “buy” rating and set a $94.00 price target on shares of Gilead Sciences in a research report on Friday, August 10th. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 18th. Morgan Stanley lifted their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 26th. Raymond James initiated coverage on shares of Gilead Sciences in a research report on Thursday, June 28th. They set a “strong-buy” rating and a $93.00 price target on the stock. Finally, Wells Fargo & Co lifted their price target on shares of Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $88.30.
The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $93.62 billion, a P/E ratio of 8.68, a price-to-earnings-growth ratio of -5.50 and a beta of 1.02.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period last year, the business posted $2.56 earnings per share. The firm’s quarterly revenue was down 20.9% on a year-over-year basis. equities research analysts forecast that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Investors of record on Friday, September 14th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.08%. Gilead Sciences’s payout ratio is 26.64%.
In related news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at $238,825,271.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 150,000 shares of company stock worth $11,141,000. 1.16% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. DnB Asset Management AS increased its stake in Gilead Sciences by 4.4% in the 2nd quarter. DnB Asset Management AS now owns 156,552 shares of the biopharmaceutical company’s stock valued at $11,090,000 after buying an additional 6,600 shares during the last quarter. Gamco Investors INC. ET AL increased its stake in Gilead Sciences by 15.4% in the 2nd quarter. Gamco Investors INC. ET AL now owns 14,980 shares of the biopharmaceutical company’s stock valued at $1,061,000 after buying an additional 2,000 shares during the last quarter. Vishria Bird Financial Group LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at $4,307,000. Intrust Bank NA increased its stake in Gilead Sciences by 10.0% in the 2nd quarter. Intrust Bank NA now owns 20,327 shares of the biopharmaceutical company’s stock valued at $1,440,000 after buying an additional 1,849 shares during the last quarter. Finally, NumerixS Investment Technologies Inc increased its stake in shares of Gilead Sciences by 199.4% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 30,389 shares of the biopharmaceutical company’s stock worth $2,137,000 after purchasing an additional 20,240 shares during the last quarter. Hedge funds and other institutional investors own 78.04% of the company’s stock.
Gilead Sciences Company Profile (NASDAQ:GILD)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.